Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma

Clinical trial NCT06880601 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06880601
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myleoma Multiple Myeloma in Relapse Multiple Myeloma Refractory

Start date: 2025-11-01
Primary completion: 2029-11-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.